Vaishampayan noted that all men who are diagnosed with metastatic, hormone-sensitive prostate cancer on androgen deprivation
become castrate-resistant within a median of 18-24 months after their initial diagnosis.
Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation
therapy for prostate cancer.
73) The increased expression, greater stability, and nuclear localization of AR in recurrent prostate cancers resistant to androgen deprivation
correlated with hypersensitivity to low levels of androgens in these tumors; androgen ablation-resistant prostate cancers required a significantly much lower concentration of dihydrotestosterone than that required by androgen-dependent tumors for stimulation of proliferative activity.
Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation
GTx is developing ACAPODENE([R]) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial evaluating toremifene citrate 80 mg for the treatment of serious side effects of androgen deprivation
therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial evaluating toremifene citrate 20 mg for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN.
Addition of radiotherapy to long-term androgen deprivation
in locally advanced prostate cancer: An open randomised phase 3 trial.
1 "Toremifene citrate increases bone mineral density in men receiving androgen deprivation
therapy for prostate cancer.
There is a clear, unmet medical need for new treatment options for prostate cancer patients, especially those with castration-resistant prostate cancer who often become resistant to androgen deprivation
therapy," commented Dr.
06 and VCOG PR 01-03: The Timing Of Androgen Deprivation
Therapy In Prostate Cancer Patients With A Rising PSA (TOAD) Collaborative Randomised Phase III Trial examined 293 patients with PSA relapse after definitive therapy to compare if immediate ADT versus delayed ADT affected OS.
One group of researchers found that primary androgen deprivation
therapy fails to improve either overall or disease-specific survival in this patient population, yet it still is widely used as the initial treatment for localized disease.
TSE: 4503) announced final results on the primary and secondary efficacy endpoints from the Phase 3 PREVAIL trial of enzalutamide in patients with chemotherapy-naE[macron]ve metastatic prostate cancer who have failed androgen deprivation
therapy and have few or no symptoms.
therapy is highly effective; however, the tumour eventually becomes resistant to the treatment and regrows in an incurable form.